Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. I-MAB ( (IMAB)) has provided an update.
Yesterday, multiple media sources reported that AbbVie is stopping its phase 1 clinical trial of lemzoparlimab (“lemzo”) as part of a combination treatment for myelodysplastic syndromes, or MDS, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback